finance.yahoo.com 20 hours ago URGENCY: 6/10
Neumora's Major Catalyst: Upcoming Depression Data
Neumora Therapeutics (NMRA) is on the brink of a significant breakthrough with its experimental depression treatment, navacaprant. As the company prepares to unveil crucial trial results, investors are eager to see if this could lead to a 1000% stock surge.
Neumora's Promising Trials
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is gearing up for a pivotal moment as it approaches the release of data from two late-stage studies, KOASTAL-2 and KOASTAL-3. With over 400 patients enrolled in each trial, the results expected in the second quarter of 2026 could significantly impact the company's stock performance.
In addition to navacaprant, Neumora is expanding its pipeline with other promising candidates. Key developments include:
- NMRA-511: Targeting agitation linked to Alzheimer's disease, with data expected in late 2026.
- NMRA-898: Currently in Phase 1 trials for schizophrenia, with results anticipated in the same timeframe.